A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

NCT03807778 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Mobocertinib

Sponsor

Takeda